http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
St. Jude Medical (STJ) Gains FDA Clearance of EnSite Precision Cardiac Mapping System
-
St. Jude Medical Announces FDA Clearance of EnSite Precision Cardiac Mapping System
-
St. Jude Medical Announces Fourth Quarter Dividend
-
St. Jude Medical (STJ) Gets CE Mark for Proclaim SCS System Conditional Labeling
-
St. Jude Medical Receives CE Mark Approval for Full Body MR Conditional Labeling for the Proclaim Elite Spinal Cord Stimulation System
-
St. Jude Medical (STJ) Announces MOMENTUM 3 Study Met Primary Endpoint
-
St. Jude Medical HeartMate 3 LVAS Demonstrated Improved Clinical Outcomes for Patients Suffering from Advanced Heart Failure
-
Eton Park Capital's 13F Shows New Stakes Twitter (TWTR), Kinder Morgan (KMI), Whitewave (WWAV), Increase in Microsoft (MSFT) (More...)
-
St. Jude Medical Announces Full-Body MRI Compatibility and Second Major Upgrade for Proclaim Elite Spinal Cord Stimulation System
-
St. Jude Medical (STJ) Granted CE Mark Approval for Quadra Allure MP CRT-P
-
St. Jude Medical Gains CE Mark Approval for MRI Labeling of its Quadra Allure MP Cardiac Resynchronization Therapy Pacemaker
-
St. Jude Medical (STJ) Presents Strong Data from AMPLATZER Amulet LAA Occluder Study
-
Largest Observational Study to Date of the St. Jude Medical AMPLATZER Amulet Left Atrial Appendage Occluder Demonstrates High Implant Success and Strong Safety Profile
-
St. Jude Medical (STJ) Announces Positive Long-Term Data from AMPLATZER PFO Occluder RESPECT Trial
-
St. Jude Medical Welcomes Landmark Stroke Data from the RESPECT Trial
-
St. Jude Medical (STJ) Announces ILUMIEN III Trial Met Primary Endpoint
-
ILUMIEN III Clinical Trial Results from St. Jude Medical Demonstrate Important Findings with Advanced Intravascular Imaging Technology
-
St. Jude Medical (STJ) Announces FDA Approval, U.S. Launch of Medical Device to Reduce Risk of Recurrent Ischemic Stroke in Patients with PFO
-
St. Jude Medical Announces FDA Approval and U.S. Launch of the First and Only Medical Device Indicated to Reduce the Risk of Recurrent Ischemic Stroke in Patients with a PFO
-
St. Jude Medical (STJ) Shareholders Approve Abbott (ABT) Merger
-
St. Jude Medical Shareholders Approve Merger with Abbott
-
St. Jude Medical Announces Data to be Presented as Late-Breaking Clinical Trials and Highlights Its Latest Cardiovascular Portfolio at the 2016 TCT Conference
-
St. Jude Medical Reports Third Quarter 2016 Results
-
St. Jude Medical (STJ) Launches ADO II AS Trial to Study Congenital Heart Defects
-
St. Jude Medical, FDA and Top Pediatric Cardiology Experts Announce New Clinical Trial to Treat Congenital Heart Defects
-
Abbott (ABT), St. Jude (STJ) Announce $1.12B Sale of Vascular Closure, Electrophysiology Businesses to Terumo
-
St. Jude Medical and Abbott to Sell Portion of Vascular Closure and Electrophysiology Businesses to Terumo Corporation
-
St. Jude Medical Announces it is Forming a Cyber Security Medical Advisory Board
-
St. Jude Medical (STJ) Granted FDA Clearance for PressureWire X Guidewire
-
St. Jude Medical Announces FDA Clearance and Launch of the New PressureWire X Guidewire Designed to Optimize PCI Procedures in Patients With Complex Anatomies
-
St. Jude Medical (STJ) Announces FDA Approval, Launch of Infinity DBS System
-
St. Jude Medical Announces U.S. Launch and First Implant of New Deep Brain Stimulation System and Directional Lead for Patients Suffering from Movement Disorders
-
St. Jude Medical (STJ) Unleashes EnSite Precision Cardiac Mapping System in Europe
-
St. Jude Medical Announces European Full Market Release of EnSite Precision Cardiac Mapping System
-
St. Jude Medical's (STJ) BurstDR Receives FDA Approval
-
St. Jude Medical Announces FDA Approval of BurstDR Stimulation, a New Superior Spinal Cord Stimulation Option for Patients Suffering from Chronic Pain
-
St. Jude Medical Announces Third Quarter 2016 Earnings Conference Call
-
St. Jude Medical (STJ) Sues Muddy Waters, MedSec
-
St. Jude Medical Brings Legal Action Against Muddy Waters and MedSec
-
St. Jude Medical (STJ) Commences AMPLATZER Amulet IDE Trial
-
St. Jude Medical Launches Global Clinical Trial to Evaluate a New Therapy Option for Patients at an Increased Risk of Stroke Due to Atrial Fibrillation
-
St. Jude Medical (STJ) Continues Refuting Muddy Waters, MedSec Allegations; Calls 'Misleading', 'Irresponsible'
-
St. Jude Medical Continues to Refute Allegations made by Muddy Waters Capital and MedSec
-
St. Jude Medical (STJ) Refutes Claims Made by Short Seller Muddy Waters
-
St. Jude Medical Refutes Muddy Waters Device Security Allegations and Reinforces Security of Devices and Commitment to Patient Safety
-
St. Jude Medical Announces Third Quarter Dividend
-
St. Jude Medical Reports Second Quarter 2016 Results
-
St. Jude Medical Continues to Expand its Heart Failure Portfolio in the U.S. to Provide Physicians Additional Options for Managing Patients Not Responding to Other Therapies
-
St. Jude Medical Announces Second Quarter 2016 Earnings Conference Call
-
St. Jude Medical Expands Its Heart Failure Portfolio with SyncAV CRT Technology, Providing Physicians Another Option for Managing Patients Not Responsive to Other Therapies

